Pefloxacin (mesylate)

Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies[1][2][3][4][5][6][7][8][9].

Product Specifications

CAS Number

[70458-95-6]

Product Name Alternative

Pefloxacinium mesylate

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Antibiotic; Bacterial; DNA/RNA Synthesis; Parasite; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pefloxacin-mesylate.html

Purity

99.73

Solubility

DMSO : 12.5 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O=C(C1=CN(CC)C2=C(C=C(F)C(N3CCN(C)CC3)=C2)C1=O)O.CS(=O)(O)=O

Molecular Formula

C18H24FN3O6S

Molecular Weight

429.46

Precautions

H302, H315, H320, H335

References & Citations

[1]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61 (3) :377-92.|[2]Hussy P, et al. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29 (6) :1073-8.|[3]Clarke AM, et al. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams. J Antimicrob Chemother. 1985 Jan;15 (1) :39-44.|[4]Jones BM, et al. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. J Antimicrob Chemother. 1986 Jun;17 (6) :739-46.|[5]Tabary X, et al. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I. Antimicrob Agents Chemother. 1987 Dec;31 (12) :1925-8.|[6]Fantin B, et al. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother. 1991 Jul;35 (7) :1413-22.|[7]Sun YW, et al. Pefloxacin and ciprofloxacin increase UVA-induced edema and immune suppression. Photodermatol Photoimmunol Photomed. 2001 Aug;17 (4) :172-7.|[8]Truffot-Pernot C, et al. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle. 1991 Mar;72 (1) :57-64.|[9]Salmon D, et al. Activities of pefloxacin and ciprofloxacin against experimental malaria in mice. Antimicrob Agents Chemother. 1990 Dec;34 (12) :2327-30.